Compare EHTH & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHTH | GANX |
|---|---|---|
| Founded | 1997 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.1M | 159.2M |
| IPO Year | 2006 | 2021 |
| Metric | EHTH | GANX |
|---|---|---|
| Price | $4.33 | $4.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $8.67 | $8.00 |
| AVG Volume (30 Days) | 263.5K | ★ 1.2M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $542,951,000.00 | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $0.24 | N/A |
| P/E Ratio | $100.55 | ★ N/A |
| Revenue Growth | ★ 16.79 | N/A |
| 52 Week Low | $3.18 | $1.41 |
| 52 Week High | $11.36 | $4.34 |
| Indicator | EHTH | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 70.23 |
| Support Level | $3.64 | $3.94 |
| Resistance Level | $4.56 | $4.34 |
| Average True Range (ATR) | 0.26 | 0.38 |
| MACD | 0.08 | 0.04 |
| Stochastic Oscillator | 75.39 | 79.01 |
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.